Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review
- 10 July 2023
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (5) , 2213-2220
Abstract
Background Melatonin is a neurohormone secreted predominantly by the pineal gland that is demonstrated to be associated with the pathogenesis of multiple sclerosis (MS). This research desires to evaluate the tolerability and beneficial effects of exogenous melatonin supplementations in patients with MS. Methods This study was executed following the PRISMA 2020 statement. Both observational and interventional studies which reported the clinical effectiveness and/or safety of melatonin supplementation in patients with MS were included in this systematic review. Ovid, PubMed, Scopus, Embase, and Web of Science databases were searched and the risk of bias in included studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools based on study design. Results Out of 1304 results of database searches, finally, 14 articles, including 7 randomized controlled trials (RCTs), 6 case–control studies, and one quasi-experimental study, were included based on the full-text review. Included phenotypes of MS were mostly relapsing-remitting MS (RRMS) (in 11 studies); it was secondary progressive MS (SPMS) in only one study, and two other studies had a mixture of the different phenotypes. The course of treatment with melatonin supplementation was between 2 weeks and 12 months. There were no substantial safety issues. Although melatonin was associated with enhanced oxidative stress and inflammation status, concerning the clinical benefits, limited studies suggested improvements in sleep conditions, cognitive outcomes, and fatigue in MS. Discussion There are insufficient data to support the regular melatonin prescription in MS. Limitations such as the small number of included studies, the diversity of the dosage, route, and duration of melatonin administration, and the diversity of assessment tests lead to unconvincing findings in this study. There is a need for future studies to achieve a comprehensive judgment on this subject.Keywords
Funding Information
- Student Research Committee, Tabriz University of Medical Sciences (grant number: 70831)
This publication has 54 references indexed in Scilit:
- Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosisBMC Neurology, 2014
- The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosisBrain, Behavior, and Immunity, 2013
- Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical courseJournal of Neuroimmunology, 2013
- The effects of whole-body cryotherapy on oxidative stress in multiple sclerosis patientsJournal of Thermal Biology, 2010
- Multiple sclerosisThe Lancet, 2008
- The contribution of nitric oxide and interferon gamma to the regulation of the neuro-inflammation in experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2007
- Melatonin in the eye: Implications for glaucomaExperimental Eye Research, 2007
- The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysisJournal of General Internal Medicine, 2005
- Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesionJournal of Experimental Medicine, 2005
- Animal modelsAnnals of Neurology, 1994